Leritrelvir
Based on 1 publication(s) in Google Scholar
Leritrelvir (RAY1216) is an orally active SARS-CoV-2 main protease slow-tight inhibitor with a Ki of 8.6 nM.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 97.92%
- CAS 番号: 2923310-64-7
- 分子式: C31H44F3N5O6
- 分子量:639.71
-
保管条件:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Leritrelvir
More
生物活性
製品説明
IC50 & Target
Ki: 8.6 nM (SARS-CoV-2 main protease)[1]
体外実験
Leritrelvir (RAY1216) has a drug-target residence time of 104 min[1].
Leritrelvir is covalently attached to the catalytic Cys145 through the α-ketoamide warhead[1].
Leritrelvir (0-1000 nM; 72 h) shows antiviral activities against SARS-CoV-2 wild type ancestral strain and variants[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Vero E6 cells inoculated with SARS-CoV-2 WT, Alpha, Beta, Delta, Omicron BA.1 and Omicron 247 BA.5 strains
-
Concentration:0-1000 nM
-
Incubation Time:72 h
-
Result:The half-maximal effective concentration (EC50) values against different SARS-CoV-2 variants were 95 nM (WT), 130 nM (Alpha), 277 nM (Beta), 97 nM (Delta), 86 nM (Omicron BA.1) and 158 nM (Omicron BA.5), respectively.
体内実験
Compound pharmacokinetics parameters in different animal species[1]
| Compound | Species | dose (mg/kg) | Cmax (nM) | Tmax (h) | AUC(0-last) (nM h) | Cl (mL/min/kg) | Vdss (L/kg) | T1/2 (h) | oral F (%) |
| Mouse | 3.0 (IV) | - | - | 7789 | 10 | 1.4 | 3.8 | - | |
| 10 (PO) | 1287 | 2.0 | 5698 | - | - | 2.6 | 22 | ||
| RAY1216 | rat | 2.0 (IV) | - | - | 4505 | 12.5 | 1.1 | 2.2 | - |
| 10 (PO) | 916 | 0.9 | 7429 | - | - | 4.3 | 33 | ||
| cynomolgus macaque | 1.0 (IV) | - | - | 1157 | 22.5 | 1.0 | 0.9 | - | |
| 5.0 (PO) | 102 | 1.5 | 458 | - | - | 14.9 | 8 |
Cmax: the maximum observed concentration of the drug collected in bodily material from subjects in a clinical study
Tmax: the time it takes to reach the maximum concentration or time to Cmax
AUC: "Area Under the Curve” and represents the total exposure of the drug experienced by the subject in a clinical study
Cl: total plasma clearance
Vdss: Steady state volume of distribution
T1/2: Half-time is the time it takes for half the drug concentration to be eliminated
oral (F%): Oral bioavailability
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female human ACE2 transgenic C57BL/6 mouse, SARS-CoV-2 infection model[1]
-
Dosage:150, 300 and 600 mg/kg/day
-
Administration:Intragastric administration, 5 days
-
Result:Protected mice infected with SARS-CoV-2 by 100%, 43% and 14% at 600, 300 and 150 mg/kg, respectively. Decreased viral titres in lungs significantly compared with the infection-only group. Reduced virus induced pathology.
-
Animal Model:Male CD-1 mouse, male SD rat and male cynomolgus macaque[1]
-
Dosage:1-10 mg/kg
-
Administration:PO or IV (Pharmacokinetic Analysis)
-
Result:Showed promising human pharmacokinetics profile.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 2923310-64-7
-
性状 Solid
-
分子量 639.71
-
分子式 C31H44F3N5O6
-
Color White to off-white
-
SMILES
O=C(C(F)(F)F)N[C@H](C(N1C[C@H](CCC2)[C@H]2[C@H]1C(N[C@@H](C[C@]3([H])CCNC3=O)C(C(NC4CCCC4)=O)=O)=O)=O)C5CCCCC5
-
別名
RAY1216
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
溶剤 & 溶解度
体外:
DMSO : 83.33 mg/mL (130.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (286 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5632 mL | 7.8160 mL | 15.6321 mL | 39.0802 mL |
| 5 mM | 0.3126 mL | 1.5632 mL | 3.1264 mL | 7.8160 mL | |
| 10 mM | 0.1563 mL | 0.7816 mL | 1.5632 mL | 3.9080 mL | |
| 15 mM | 0.1042 mL | 0.5211 mL | 1.0421 mL | 2.6053 mL | |
| 20 mM | 0.0782 mL | 0.3908 mL | 0.7816 mL | 1.9540 mL | |
| 25 mM | 0.0625 mL | 0.3126 mL | 0.6253 mL | 1.5632 mL | |
| 30 mM | 0.0521 mL | 0.2605 mL | 0.5211 mL | 1.3027 mL | |
| 40 mM | 0.0391 mL | 0.1954 mL | 0.3908 mL | 0.9770 mL | |
| 50 mM | 0.0313 mL | 0.1563 mL | 0.3126 mL | 0.7816 mL | |
| 60 mM | 0.0261 mL | 0.1303 mL | 0.2605 mL | 0.6513 mL | |
| 80 mM | 0.0195 mL | 0.0977 mL | 0.1954 mL | 0.4885 mL | |
| 100 mM | 0.0156 mL | 0.0782 mL | 0.1563 mL | 0.3908 mL |
Leritrelvir 関連分類
HY-153121 関連分類
Powered by Bioz